Brief: Galera Announces Presentation Of Phase 3 Roman Long-Term Follow-Up Data At 2022 American Society For Radiation Oncology (Astro) Annual Meeting

Obsidian Therapeutics

26/10/2022 18:42

Oct 26 (Reuters) - Galera Therapeutics Inc  GRTX.O :
    * GALERA ANNOUNCES PRESENTATION OF PHASE 3 ROMAN LONG-TERM
FOLLOW-UP DATA AT 2022 AMERICAN SOCIETY FOR RADIATION ONCOLOGY
(ASTRO) ANNUAL MEETING
    * GALERA THERAPEUTICS INC - REMAINS ON TRACK TO SUBMIT NDA
TO U.S.
FDA FOR AVASOPASEM FOR RADIOTHERAPY-INDUCED SEVERE ORAL
MUCOSITIS BY END OF 2022
    * GALERA THERAPEUTICS INC - META-ANALYSIS OF ROMAN AND
GT-201
(PHASE 2B) SUPPORTS EFFICACY ACROSS TRIALS AND KEY SOM ENDPOINTS

Source text for Eikon:  ID:nGNXdRxqg 
Further company coverage:  GRTX.O 
 ((Reuters.Briefs@thomsonreuters.com;))